COVID-19 Vaccine Response in People with Multiple Sclerosis

Area of Science:

• Immunology
• Neurology
• Vaccinology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Disease-modifying therapies (DMTs) are crucial for managing MS progression.
• The immunogenicity of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in MS patients on DMTs requires investigation.

Purpose of the Study:

• To investigate the impact of various DMTs on the immune response to SARS-CoV-2 vaccines in individuals with MS.
• To assess seroconversion rates and antibody titers following vaccination in relation to DMT use.
• To explore factors influencing vaccine response, including DMT type, treatment duration, and vaccine type.

Main Methods:

• A cohort of 473 MS patients provided dried blood spot samples for antibody testing.
• Data on COVID-19, vaccination history, and DMT use were collected.
• Antibody titers were analyzed, and logistic regression was used to determine the odds of seroconversion based on DMT use.

Main Results:

• Anti-CD20 monoclonal antibodies and fingolimod were associated with significantly lower seroconversion rates compared to no DMT.
• Treatment duration and timing of anti-CD20 therapy impacted vaccine response.
• Vaccine type influenced seroconversion, except in patients on anti-CD20 medications.
• Preliminary T-cell immunity data indicated measurable responses in 40% of seronegative individuals.

Conclusions:

• Certain DMTs, particularly anti-CD20 therapies and fingolimod, can attenuate the serological response to SARS-CoV-2 vaccines in MS patients.
• Recommendations for managing vaccination in this population are provided.
• Understanding T-cell responses may offer further insights into vaccine efficacy in MS patients on DMTs.